Vascepa has taken some big risks over the years...and has won some and lost some...but even though Amarin feels victimized now...fighting back as a small biotech, may not be the best policy...Amarin can merge with a BP, more able to manage such risks, and can continue with the appeal case and the successful roll out of Vascepa all over the world.
Fully agree. Sadly, Du's ruling transformed Amarin from soaring eagle to wounded duck. The situation we face today is totally different than last week. Since December R-It label, our stock has fallen 80-85%. Management is largely silent since Monday's bloodbath (1 PR).The US market is a only a wildcard. Sell the company, and perhaps I can purchase shares of the buyer. Vascepa can be a great asset in the right hands. JT and the gang fumbled it.
News 
Market Data 
Discover 
AI
